PDGFR gene re-arrangement
2 drugsPredictive biomarker for patient selection in 9 indications
2
Approved Drugs
9
Indications
2
Companies
PDGFR gene re-arrangement is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 9 indications including Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic/Myeloproliferative Diseases. Explore the targeted therapies, indications, testing methods, and companies developing PDGFR gene re-arrangement drugs below.
Search PDGFR gene re-arrangement Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting PDGFR gene re-arrangement
| Drug | Company | Therapeutic Area |
|---|---|---|
| IMATINIB MESYLATE | Viatris | Oncology |
| IMKELDI | SHORLA ONCOLOGY | Oncology |
PDGFR gene re-arrangement Indications
Chronic Myeloid Leukemia Acute Lymphoblastic Leukemia Myelodysplastic/Myeloproliferative Diseases Aggressive Systemic Mastocytosis Hypereosinophilic Syndrome Chronic Eosinophilic Leukemia Dermatofibrosarcoma Protuberans Gastrointestinal Stromal Tumor Gastrointestinal Stromal Tumors